195 related articles for article (PubMed ID: 19947907)
1. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
Harb G; Lebel F; Battikha J; Thackara JW
Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
[TBL] [Abstract][Full Text] [Related]
3. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
Thomas JR; Yocum RC; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
[TBL] [Abstract][Full Text] [Related]
4. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
Vaughn DE; Muchmore DB
Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial of recombinant human hyaluronidase-facilitated subcutaneous versus intravenous rehydration in mild to moderately dehydrated children in the emergency department.
Spandorfer PR; Mace SE; Okada PJ; Simon HK; Allen CH; Spiro DM; Friend K; Harb G; Lebel F;
Clin Ther; 2012 Nov; 34(11):2232-45. PubMed ID: 23062548
[TBL] [Abstract][Full Text] [Related]
7. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
[TBL] [Abstract][Full Text] [Related]
8. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Dolton MJ; Chesterman A; Moein A; Sink KM; Waitz A; Blondeau K; Kerchner GA; Hu N; Brooks L; Wetzel-Smith MK; Roden A; Deshmukh A; Peng K; Carrasco-Triguero M; Smith J; Ostrowitzki S; Quartino A
Clin Pharmacol Ther; 2021 Nov; 110(5):1337-1348. PubMed ID: 34347883
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
11. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
Morcos PN; Zhang X; McIntyre C; Bittner B; Rowell L; Hussain Z
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):537-48. PubMed ID: 23547849
[TBL] [Abstract][Full Text] [Related]
13. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Morrow L; Muchmore DB; Ludington EA; Vaughn DE; Hompesch M
Diabetes Technol Ther; 2011 Oct; 13(10):1039-45. PubMed ID: 21714645
[TBL] [Abstract][Full Text] [Related]
14. Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer.
Kang DW; Bittner B; Sugarman BJ; Zepeda ML; Printz MA
PLoS One; 2021; 16(7):e0254765. PubMed ID: 34292990
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans.
Shi GH; Connor RJ; Collins DS; Kang DW
AAPS PharmSciTech; 2021 Jan; 22(1):39. PubMed ID: 33409604
[TBL] [Abstract][Full Text] [Related]
17. Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats.
Styles IK; Feeney OM; Nguyen TH; Brundel DHS; Kang DW; Clift R; McIntosh MP; Porter CJH
J Control Release; 2019 Dec; 315():85-96. PubMed ID: 31655131
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
Dychter SS; Ebel D; Mead TR; Yocum RC
Curr Ther Res Clin Exp; 2009 Dec; 70(6):421-38. PubMed ID: 24692835
[TBL] [Abstract][Full Text] [Related]
19. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study.
Thomas JR; Yocum RC; Haller MF; von Gunten CF
J Palliat Med; 2007 Dec; 10(6):1312-20. PubMed ID: 18095810
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Shpilberg O; Jackisch C
Br J Cancer; 2013 Sep; 109(6):1556-61. PubMed ID: 24002601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
